New England Journal of Medicine publishes results showing divarasib significantly improves progression-free and overall survival in KRAS G12C-mutated non-small-cell lung cancer.

A phase 3, open-label, randomized trial published in The New England Journal of Medicine found that divarasib significantly improved outcomes for patients with KRAS G12C-mutated non-small-cell lung cancer. The median progression-free survival was 9.8 months with divarasib compared to 5.7 months with control treatment (hazard ratio, 0.58; P<0.001). The median overall survival was 17.7 months with divarasib versus 12.0 months with control treatment (hazard ratio, 0.56; P<0.001). Divarasib also showed a higher confirmed response rate (58.4% vs. 32.3%) and fewer grade 3 or 4 treatment-related adverse events (24.6% vs. 34.5%) compared to control.

Context

KRAS G12C mutations are present in a notable percentage of non-small-cell lung cancer cases, which is one of the most common types of lung cancer. Historically, targeted therapies for this mutation have been limited, making the development of effective treatments critical. The trial published in The New England Journal of Medicine represents a pivotal moment in cancer research, offering hope for improved therapies.

Why it matters

The findings from this trial highlight a significant advancement in the treatment of KRAS G12C-mutated non-small-cell lung cancer, a subtype that has historically been challenging to treat. Improved progression-free and overall survival rates could lead to better patient outcomes and quality of life. This research may influence treatment protocols and options for oncologists and patients alike.

Implications

The successful outcomes associated with divarasib could lead to a shift in standard care practices for patients with KRAS G12C mutations. Patients may experience extended survival and improved quality of life with this new treatment option. Pharmaceutical companies may also invest more in research targeting similar mutations, potentially leading to more breakthroughs in cancer therapies.

What to watch

As the results gain attention, healthcare providers may begin to incorporate divarasib into treatment regimens for eligible patients. Regulatory bodies could expedite the approval process for divarasib based on these promising results. Ongoing studies may also explore the long-term effects and potential combination therapies involving divarasib.